Welcome to our dedicated page for Polyrizon news (Ticker: PLRZ), a resource for investors and traders seeking the latest updates and insights on Polyrizon stock.
Polyrizon Ltd. (Nasdaq: PLRZ) generates news as a development-stage biotechnology company focused on intranasal hydrogels and barrier-forming nasal sprays. Company announcements highlight progress across its Capture and Contain™ (C&C) and Trap & Target™ (T&T) platforms, including updates on allergy, viral exposure reduction, and intranasal drug delivery programs.
Readers following Polyrizon news can expect coverage of preclinical study results, regulatory interactions, and product branding milestones. Recent press releases describe positive in-vitro data for PL-14 Allergy Blocker, including allergen-blocking performance compared with a standard comparator, and the completion of a branding process that will see PL-14 marketed as NASARIX™. Other updates focus on PL-16 Viral Blocker, a non-pharmacological intranasal hydrogel spray designed to form a temporary physical barrier on the nasal mucosa, with reported preclinical evidence of protection against certain respiratory viruses.
Polyrizon also reports on the advancement of its intranasal naloxone hydrogel within the Trap & Target™ platform. News items detail mucoadhesion and permeation studies comparing the formulation to a marketed intranasal naloxone product, as well as broader commentary on the potential role of enhanced mucosal residence time in emergency opioid overdose reversal.
In addition to R&D and regulatory milestones, Polyrizon’s news flow includes strategic and corporate developments. The company has disclosed plans to explore revenue-generating investment opportunities in sectors such as defense, aviation, artificial intelligence, and real assets, alongside continued focus on its core medical pipeline. Investors and observers can use this news stream to monitor scientific progress, FDA-related steps such as pre-submission meetings and Pre-Request for Designation filings, capital structure actions like reverse share splits, and broader strategic decisions that may influence the PLRZ stock story over time.
Polyrizon (Nasdaq: PLRZ) initiated a human factors/usability study for NASARIX™, its intranasal allergy blocker, executed to align with FDA human factors and usability engineering guidance. The program aims to confirm labeling, instructions for use, and user interaction, to de-risk downstream regulatory review and support a streamlined path toward clinical development.
Successful completion could provide regulatory evidence of readiness for clinical evaluation and supports the company’s plan to start clinical trials in Q3 2026. The company is currently a pre-clinical-stage biotechnology developer of intranasal protective solutions.
Polyrizon (Nasdaq: PLRZ) said on January 13, 2026 that its board authorized exploring strategic investments in revenue-generating operating companies in defense, aviation, and artificial intelligence (AI). The company emphasized it remains fully committed to advancing its core intranasal medical pipeline, including PL-14, PL-16 and the Trap & Target intranasal delivery platform.
The board said it will leverage a reported strong cash position and a debt-free balance sheet to pursue selective investments intended to generate near-term revenue while maintaining focus on clinical and regulatory progress.
Polyrizon (Nasdaq: PLRZ) announced completion of the branding process for its PL-14 allergy blocker, which will be marketed as NASARIX™. NASARIX™ uses Polyrizon's proprietary Capture and Contain™ (C&C) hydrogel intranasal spray technology intended to form a physical barrier against allergens and viruses. The company completed trademark screening and linguistic evaluations across the U.S. and European markets to support brand viability and regulatory alignment. Management framed the naming as a milestone toward commercial readiness and said NASARIX™ introduction will align with ongoing clinical and regulatory progress.
Polyrizon (Nasdaq: PLRZ) reported in-vitro pre-clinical results for its PL-14 Allergy Blocker showing significantly reduced transfer of the house dust mite allergen Der p 1 versus the standard comparator HPMC in a validated Transwell permeability model.
Key data: PL-14 reduced Der p 1 transfer at all time points (1, 2, 4, 6, 24 hours) with p ≤ 0.0042. At 1 hour mean Der p 1 was ~20.6 ng for PL-14 versus ~1,354.4 ng for HPMC; HPMC rose to ~5,201.2 ng at 24 hours while PL-14 peaked at ~141.2 ng at 4 hours. The company said it will advance PL-14 toward clinical studies to define regulatory pathway and real-world benefit.
Polyrizon (Nasdaq: PLRZ) highlighted its PL-16 Viral Blocker nasal spray as a complementary, non-pharmaceutical layer of protection during the intensifying 2025–2026 U.S. flu season. Public-health context includes CDC estimates of at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths, and a reported ~3 million fewer vaccine doses administered compared with last year.
Polyrizon describes PL-16 as a hydrogel that forms a temporary physical barrier on nasal mucosa; preclinical in‑vitro studies reportedly showed over 90% protection of cells from varied viruses. On Dec 19, 2025 the company submitted a Pre-Request for Designation to the FDA as an OTC product to reduce viral exposure.
Polyrizon (Nasdaq: PLRZ) said on Dec 29, 2025 that its board has authorized exploration of realistic investments in revenue-generating real assets while maintaining focus on its core intranasal medical pipeline.
The company reiterated commitment to product development, preclinical and clinical studies, and regulatory progress for programs including PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target intranasal drug-delivery platform. The board cited the company’s strong cash position and debt-free balance sheet as enabling factors and said updates will be provided if material developments occur.
Polyrizon (PLRZ) said on Dec 19, 2025 it submitted a Pre-Request for Designation (Pre-RFD) to the U.S. FDA for PL-16 Viral Blocker, a non‑pharmacological intranasal product designed to form a temporary physical barrier on the nasal mucosa to reduce exposure to influenza and cold viruses.
The company reported that PL-16 showed over 90% protection in cell-based tests and that the Pre-RFD opens a formal regulatory dialogue about the appropriate pathway based on formulation and physical mode of action.
The release cites CDC model estimates for the 2025–2026 flu season (at least 2.9M symptomatic illnesses, 1.4M medical visits, 30,000 hospitalizations, and 1,200 deaths) as context for respiratory‑infection risk.
Polyrizon (Nasdaq: PLRZ) reported preclinical results for its intranasal naloxone hydrogel on December 11, 2025, showing three supporting data pillars: stability, superior mucoadhesion versus a marketed product (p < 0.0001), and rapid permeation comparable to the commercial benchmark.
The company completed permeation studies in a validated artificial membrane system and found no statistically significant difference in naloxone diffusion rates versus the reference product, indicating enhanced nasal residence time did not delay drug permeation. Polyrizon says these results support potential advancement of the candidate and highlight its Trap & Target™ hydrogel as a way to combine mucosal retention with fast onset.
Polyrizon (Nasdaq: PLRZ) completed an FDA pre-submission meeting on Dec 8, 2025 for its PL-14 Allergy Blocker intranasal spray.
The company presented its proposed manufacturing process, analytical and quality controls, stability program, biocompatibility package, and additional preclinical studies aligned with FDA guidance for nasal spray products. Polyrizon outlined a clinical development strategy with trials expected to commence in 2026. A market report projects the global allergen blocker market to reach USD $210M by 2033.
Polyrizon (Nasdaq: PLRZ) announced a pivotal manufacturing milestone on December 2, 2025, producing larger-scale batches of its flagship intranasal hydrogel, PL-14 Allergy Blocker, with runs meeting specifications for consistency, stability, and quality.
The successful CDMO production validates the company’s Capture & Contain™ (C&C) platform manufacturing strategy, enables supply for planned clinical trials in 2026, and supports potential future commercial scale-up. The company highlights market opportunities in seasonal allergic rhinitis (estimated USD 11.14B in 2025) and influenza markets while noting continued R&D on Trap & Target™ (T&T) for nasal drug delivery.
FAQ
What is the current stock price of Polyrizon (PLRZ)?
What is the market cap of Polyrizon (PLRZ)?
